---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-036837"
form_type: "8-K"
ticker: "ICU"
cik: "0001831868"
company_name: "SeaStar Medical Holding Corp"
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:21:10.316489+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SeaStar Medical to restate 2022 annual and 2023 interim financials over warrant and forward purchase accounting

## Summary
- Restatement covers FY 2022 and quarters ended Mar 31, Jun 30, Sep 30, 2023.
- Private placement and PIPE warrants must be reclassified from equity to liability and remeasured at fair value each period.
- Prepaid forward purchase agreements should be accounted for as hybrid instruments with an embedded derivative liability.
- Company expects to disclose a material weakness in internal controls over financial reporting in its Form 10-K.
- Restatement impacts non-cash items only; audit committee discussed with both prior and current auditors.

## SEC filing metadata
- accession: 0000950170-24-036837
- form_type: 8-K
- ticker: ICU
- cik: 0001831868
- company_name: SeaStar Medical Holding Corp
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 4.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831868/000095017024036837/0000950170-24-036837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831868/000095017024036837/icu-20240321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-036837
- JSON: https://secwatch.observer/filing/0000950170-24-036837.json
- Plain text: https://secwatch.observer/filing/0000950170-24-036837.txt

## Key facts
- Auditor Changes
  SeaStar Medical Holding Corp reported that prior financial statements should not be relied upon.
  - Action: non reliance
  source text: On March 21, 2024, after discussion with the Company’s management, the Audit Committee determined that a restatement of the Company’s audited financial statements for the fiscal year ended December 31, 2022 and unaudited interim financial statements for the fiscal quarters ended March 31, 2023, June 30, 2023 and September 30, 2023 would be appropriate
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831868/000095017024036837/0000950170-24-036837-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.